Bio-Techne Corporation (NASDAQ: TECH) announces an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar. “Mdxhealth is the ideal acquirer of our ExoDx Prostate test and CLIA-certified laboratory,” said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. “Mdxhealth has made several strategic moves over the past few years to position the company as a leader in urology and prostate cancer diagnostics. The addition of ExoDx Prostate to their portfolio accelerates their leadership in this market.”
Read the full article: Bio-Techne Announces Exosome Diagnostics Divestiture //
Source: https://www.prnewswire.com/news-releases/bio-techne-announces-exosome-diagnostics-divestiture-302522475.html